A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: unbiased (1), impartial (11), pale (37)

Atezolizumab-Carboplatin(AUC5)-Etoposide(IV/PO)

Description
Chemotherapy Protocol LUNG CANCER– SMALL CELL (SCLC) ATEZOLIZUMAB-CARBOPLATIN (AUC5)-ETOPOSIDE(IV/PO) Regimen  Lung - Atezolizumab-Carboplatin (AUC5)-Etoposide(IV
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-small-cellSCLC/Atezolizumab-CarboplatinAUC5-EtoposideIVPO.pdf

EC-DPH SC (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab+Trastuzumab SC)

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-DOCETAXEL-PERTUZUMAB / TRASTUZUMAB SC (EC-DPH SC) Regimen  Breast Cancer – Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab / Tra
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-SC-Cyclophosphamide-Epirubicin-Docetaxel-PertuzumabTrastuzumab-SC.pdf

Endometrial-Dostarlimab

Description
Chemotherapy Protocol GYNACOLOGICAL CANCER Dostarlimab Regimen  Endometrial - Dostarlimab Indication  Dostarlimab is indicated for patients with; - prove
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/Dostarlimab.pdf

Carfilzomib-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib-Dexamethasone (20) Regimen • Myeloma – Carfilzomib-Dexamethasone (20) Indication • Carfilzomib in combination with dexame
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib-dexamethasone20-ver1.pdf

Carfilzomib(14 day)-Dexamethasone(20) Ver1

Description
Chemotherapy Protocol MYELOMA Carfilzomib (14 day)-Dexamethasone (20) Regimen  Myeloma – Carfilzomib-Dexamethasone (20) Indication  Carfilzomib in combination wi
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/carfilzomib14-day-dexamethasone20-ver1.pdf

Durvalumab_14day

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (14 day) Regimen • NSCLC - Durvalumab (14 day) Indication • Stage 3 NSCLC after radical chemoradio
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab-14day.pdf

Durvalumab(28day-1500mg)

Description
Chemotherapy Protocol LUNG CANCER – NON-SMALL CELL (NSCLC) Durvalumab (28 day – 1500mg) Regimen • NSCLC - Durvalumab (28 day – 1500mg) Indication • Du
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Durvalumab28day-1500mg.pdf

InP-Bleomycin-Cisplatin-Etoposide (5 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 5 Day) In-Patient Regimen Regimen Germ Cell – InP-Bleomycin-Cisplatin-Etoposide (5 day BEP)
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/InP-Bleomycin-Cisplatin-Etoposide-5-day-BEP-Ver1.2.pdf

Bleomycin-Cisplatin-Etoposide (3 day BEP) Ver1.2

Description
Chemotherapy Protocol GERM CELL BLEOMYCIN-CISPLATIN-ETOPOSIDE (BEP 3 Day) Regimen Germ Cell – Bleomycin-Cisplatin-Etoposide (3 day BEP) Indication In
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Germcell/Bleomycin-Cisplatin-Etoposide-3-day-BEP-Ver1.2.pdf

Pembrolizumab2mg/kg

Description
Chemotherapy Protocol LUNG CANCER Pembrolizumab (2mg/kg) Regimen • NSCLC – Pembrolizumab (2mg/kg) Indication • Pembrolizumab is recommended as an option f
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lung-cancer-non-small-cellNSCLC/Pembrolizumab2mgkg.pdf
191 to 200 of 265
Previous … 18 19 20 21 22 … Next